607 results about "Diabrezide" patented technology

The invention relates to the extraction and / or presentation of glucose concentrations estimated as a function of time into a format that facilitates conveyance of the underlying information. More particularly, short term actions, such as exercise, diabetes drug treatment, and / or food intake, are correlated to glucose response profiles. Optionally, glucose concentration responses are back correlated to parameters, such as time, exercise, diabetes drug treatment and / or food intake. The resulting correlated data are output to the user in a time compressed format, in video format, and / or as a cluster allowing diagnosis and treatment information to be more readily determined and used. These information presentations are useful for both the medical professional and the end user. The information presentation is preferably used with a noninvasive, implantable, semi-continuous, and / or continuous analyte analyzer, such as a glucose concentration analyzer.

The present invention is directed to a novel Afx response element comprising the nucleotide sequence AACATGTT, said nucleotide sequence having a DNA binding site for the human fork head transkription factor Afx. The invention also relates to the use of the Afx response element in the screening for genes as diabetes drug targets and in the bioinformatic analysis of the human genome, said genes in turn being useful in other screening methods for compounds modifying the insulin receptor signaling pathway. A further aspect of the invention is a vector construct comprising the novel nucleotide sequence, a host cell transformed with said vector construct as well as the fusion protein expressed by said host cell.

The present invention relates to the finding that certain DPP-4 inhibitors are particularly suitable for treating and / or preventing metabolic diseases, particularly diabetes, in patients with insufficient glycemic control despite a therapy with an oral and / or a non-oral antidiabetic drug.

A computer system for ongoing monitoring and providing medication dosage recommendation to diabetic patients includes: a database for storing patient data; patient database access including one of web access, touch tone telephone access and speech recognition access; a server; a first set of programs contained within the server for processing the patient data and interfacing the data base accesses; a computer terminal connected to the server through the World Wide Web containing the set of programs including the specific interface to the system for a patient's physician to enter patient specific parameters relevant to compute one of the insulin and other medication dosage; a second set of programs contained within the server for diabetic management for interface by a patient and the patient physician by the patient means of database access; and the second set of programs to be used to enter the current blood glucose, the planned intake of carbohydrates, and to generate a recommendation of one of a dosage of diabetic medication and a quantity of glucose for intake.

The invention relates to antidiabetic medications which are suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia, inter alia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions. The medication is a mono treatment with a DPP-4 inhibitor <preferably linagliptin> or a combination treatment with a DPP-4 inhibitor and a second and / or third antidiabetic.

Methods for identifying Rheb effectors are provided. The Rheb effectors can be Rheb agonists or antagonists and can be utilized as lead compounds for the development of drugs for the treatment of diabetes or diseases associated with abnormal cell growth. Non-human, transgenic animals over-expressing Rheb protein, and methods of making such transgenic animals, are also provided.

The present invention provides pharmaceutical compositions comprising: (a) a modulator of hepatic parasympathetic tone, (b) at least one diabetes drug, and (c) a pharmaceutically acceptable carrier. The present invention includes methods for the treatment and / or prevention of insulin resistance, type 2 diabetes, impaired glucose intolerance, and other associated disorders with pharmaceutical compositions described herein. The invention also provides for a kit comprising a pharmaceutical composition and instructions for its use.

The invention relates to an andrographolide derivative, which has the structure as shown in a general formula I: wherein, R1, R2 and R3 are the same or different hydrogen, substituted or non-substituted organic acid radical, inorganic acid radical, alkyl, aryl or heteroaryl, while at least one of R1, R2 and R3 is R-lipoic acid or S-lipoic acid or the mixture of R-lipoic acid and S-lipoic acid or the corresponding dihydrolipoic acid or acetylcysteine radical of R-lipoic acid or S-lipoic acid; the derivative has good anti-tumor effect, and the derivative can cause apoptosis of tumor cells, directly eliminate gram positive bacteria, staphylococcus aureus and sensitivities MRSA5676 and MRSA5677, inhibit the QS system of gram negative bacteria and pseudomonas aeruginosa and inhibit and damage the formation of the bio-film of pseudomonas aeruginosa; the product has prominent hypoplycemic effect and is suitable for the preparation of the medicines that can cure cancers, inflammations, diabetes mellitus and bacterial and viral infection.

The invention discloses an application of ergot sterioside, which refers to the application for preparing diabetes pharmaceutical preparation with only ergot sterioside or composition of ergot sterioside and medical acceptable drug carriers, and develops a novel medical value for ergot sterioside.

The present invention is directed to a method for treating a patient suffering from the metabolic syndrome, Type 2 diabetes, obesity, or prediabetes, comprising the step of increasing the ratio of dopaminergic neuronal to noradrenergic neuronal activity within the hypothalamus of the central nervous system of the patient. In another aspect, the present invention is directed to a method for treating a patient suffering from the metabolic syndrome, Type 2 diabetes, obesity, or prediabetes, comprising the step of: administering to a patient suffering from the metabolic syndrome, Type 2 diabetes, obesity, or prediabetes a pharmaceutical composition comprising (1) at least one compound that stimulates an increase in central dopaminergic neuronal activity level in the subject, and (2) at least one compound that stimulates a decrease in central noradrenergic neuronal activity level in the subject. The present invention is also directed to pharmaceutical compositions that include the above compounds and a pharmaceutically acceptable carrier.

To provide novel crystals useful as an ingredient for the production of a diabetes remedy. The invention is concerned with α-form crystal and β-form crystal of (R)-2-(2-aminothiazol-4-yl)-4′-[2-[(2-hydroxy-2-phenyleth-yl)amino]ethyl]acetanilide. The α-form crystal does not exhibit hygroscopicity and has stability such that it can be used as a medicine, and is useful for mass synthesis in the industrial production. The β-form crystal does not relatively exhibit hygroscopicity and is also useful as a production intermediate of the α-form crystal.

The invention discloses preparation and application of a pH glucose dual sensitive hydrogel. The hydrogel is formed by crosslinking of phenylboronic acid modified chitosan and an active functional group equipped crosslinking agent through imine bond and phenylboronic acid ester two dynamic covalent bonds, and has injectability and self-repairing performance. The imine bond is stable under normal physiological pH value, can hydrolyze under slightly acidic pH value, and is sensitive to the pH value change. Phenylboronic acid ester can undergo competing reaction in the presence of glucose, so that hydrogel can have network structure change so as to have glucose responsiveness. By regulating the structure, composition and functional groups of phenylboronic acid modified chitosan and the crosslinking agent, the rheological properties of the hydrogel can be adjusted, and activity release of the hydrogel to a substrate can be controlled. The system can be used as a drug carrier to convey various antitumor and diabetes drugs, also can be applied as a tissue engineering scaffold material to cell encapsulation and culture, thus realizing synergic treatment on the drug and cell level.

The invention relates to the field of diabetes-related drugs, in particular to an SGLT2 inhibitor containing the structure of five-membered heteroaromatics tolylene glucoside and the preparation method thereof and application thereof for preparing the drugs of diabetes, wherein, the group is defined in the specification.

The present invention relates to an extended release dosage form of highly water-soluble antidiabetic drug metformin or its pharmaceutically acceptable salts. This invention also relates to methods for preparing the extended release dosage forms of metformin or its pharmaceutically acceptable salts.

The invention provides C-aryl glucoside derivatives, a preparation method and an application thereof, relates to the field of medicines relative to diabetes and particularly relates to a sodium-dependent glucose transport protein type-2 (SGLT-2) inhibitor containing a C-aryl glucoside structure, the preparation method of the inhibitor and the application of the inhibitor in preparation of diabetes medicines. Definition of each substituent groups in general formula (I) is same as that in the description.

The invention relates to the field of natural drug and medicinal chemistry, in particular to ursane-type pentacyclic triterpenoid amino acid derivatives (I), and the preparation method and the medicinal application thereof. The compounds have effect on inhibiting glycogen phosphorylase, and can be used for preparing drugs for resisting diabetes, cerebral ischemia, cardiovascular diseases, hyperlipemia, obesity, atherosclerosis and tumor. The invention also relates to the preparation method of the compounds and drug preparations containing the compounds.

The invention discloses an amorphous substance of canagliflozin and a preparation method of the amorphous substance. Through DSC (Differential Scanning Calorimetry) scanning, the amorphous substance is found to have an endothermic peak within the temperature range of 53-63 DEG C and has characteristic absorption peaks at the wavelengths of about 832cm<-1> and 809cm<-1> in an infrared spectrogram. The invention also discloses an application of the amorphous substance to preparation of drugs for treating type-2 diabetes.

The invention provides a compound preparation containing a DPP-IV (dipeptidyl peptidase-IV) inhibitor and a type-II diabetes medicine and a preparation method thereof. According to the invention, two effective pharmaceutical ingredients are respectively prepared into a quick-release part and a slow-release part (controlled-release part) and then prepared into the compound preparation finally; the problem of combining the DPP-IV inhibitor with other diabetes medicines is solved; compliance of patients is increased; the curative effects and durations of medicines are increased maximally; the compound preparation disclosed by the invention has good effects and practical significance for treating or preventing one or more symptoms, such as type-I diabetes, type-II diabetes, hyperglycemia and impaired glucose tolerance.

An extract of mulberry leaf contains general alkaloid and general flavone, and is prepared through extracting, removing impurities, concentrating, eluting, drying and mixing. It can be used to prepare the medicines for preventing and treating diabetes and its complications.

The present invention relates to a plant extract with the action of resisting diabetes, its application and preparation method. The extract is a kind of acetogenins extracted from branck, leaf, trunk, bark, root, seed and fruit skin of annona squamosa plant as raw material. The compound acetogenins can be made into various dosage forms for curing diabetes, and its preparation method can adopt oneor several processes of solvent extraction process, resin adsorption process, supercritical CO2 extraction process and conventional drying process.

The invention refers to the herbal composition which consists of: the plant of centaury (Centauri herba) 12.3% by wt., the root of dandelion (Teraxaci radix) 9.7% by wt., the fruit of juniper (Juniperi communis fructus) 6.2% by wt., the plant of nettle (Urticae herba) 7.4% by wt., the root of nettle (Urticae radix) 7.0% by wt., the root of chicory (Cichorii radix) 17.7% by wt., the leaf of black mulberry (Morus nigra folium) 7.4% by wt., the flower of yarrow (Achilleae millefolii flos) 3.5% by wt., the leaf of bilberry (Vaccinii myrtilli folium) 6.6% by wt., the pod of beans (Phaseoli fructus sine semeni) 14.4% by wt., and the root of valerian (Valerianae officinalis radix) 7.8% by wt., and to the medicament against diabetes mellitus type II obtained from it. The medicament is anticipated to be administered perorally in form of tea, a tincture and a pill.

The invention relates to the field of medicines related to diabetes. More specifically, the invention relates to a sodium galactose transporter type 2 (SGLT2) inhibitor having a structure of C-glucoside derivatives containing saturated six-membered ring, a preparation method thereof, a pharmaceutical composition containing the derivatives and application of the derivatives in preparing diabetes medicines, wherein X and Y are defined as the followings: (1) X = Y = carbon atom; (2) X = Y = nitrogen atom; (3) X = nitrogen atom and Y = oxide atom; and (4) X = nitrogen atom and Y = carbon atom. Other groups are defined as specification.

The invention relates to an application of a black raspberry extract in preparing an anti-diabetic medicine, and an application of the black raspberry extract in preventing type-II diabetes mainly characterized by glucose metabolic disorders, beta islet cell damage and insulin resistance. A novel anti-diabetic medicine preparation provided by the invention takes the black raspberry extract as an active ingredient, and the total effective dose is 1-100mg / kg / d. According to the novel anti-diabetic medicine preparation provided by the invention, the black raspberry extract can be compounded with the diabetes treatment medicines on the current market including sulfonylureas, biguanides or thiazolidinediones to prepare a compound preparation. The black raspberry extract can promote islet cell multiplication and inhibit the PTP1B activity; and meanwhile, in-vivo study finds that the black raspberry extract can be used for improving the increase of the mice blood glucose level caused by alloxan and has an obvious effect in reducing blood glucose. Through verification, the blood glucose reducing effect of the black raspberry fruit or leaf extract is superior to that of the selected positive medicine diaformin.

The invention provides a preparation method of high-glucose activated mesenchymal stem cells, and relates to a high-glucose activated mesenchymal stem cell injection and application thereof in preparation of diabetic drugs. The preparation method of the high-glucose activated mesenchymal stem cells comprises the following steps: when culturing an umbilical cord, bone marrow or the mesenchymal stem cells which are extracted separately until fusion reaches 40-50%; adding a glucose solution of which the final concentration is 20-50 mmol / L; culturing for 48+ / - 2 hours; and when fusion of the mesenchymal stem cells reaches 75-80%, digesting, neutralizing, washing and collecting the high-glucose activated mesenchymal stem cells. The high-glucose activated mesenchymal stem cell injection comprises the high-glucose activated mesenchymal stem cells, human albumin, compound vitamin, mannitol, glucose and normal saline. The high-glucose activated mesenchymal stem cell injection can be used for treating type-2 diabetes.

The invention discloses an azacyclic transition metal zinc complex containing multiple coordination sites, and a preparation method and application of the azacyclic transition metal zinc complex. The azacyclic transition metal zinc complex is a 1-(benzotriazole-1-methyl)-1-(2-ethyl imidazole) zinc complex, and has a molecular formula of [Zn (SCN) 2(C12H13N5)2]. The azacyclic transition metal zinc complex, namely, the 1-(benzotriazole-1-methyl)-1-(2-ethyl imidazole) zinc complex provided by the invention has a higher inhibiting effect for alpha-amylase, and the inhibiting effect of the 1-(benzotriazole-1-methyl)-1-(2-ethyl imidazole) zinc complex is much higher than that of singly-used 1-(benzotriazole-1-methyl)-1-(2-ethyl imidazole) or transition metal salt for the alpha-amylase and is higher than that of commonly-used hypoglycemic agent acarbose for the alpha-amylase. Therefore, the azacyclic transition metal zinc complex is proved to have a good hypoglycemic effect so as to be effectively used for preparing medicines for treating diabetes mellitus, and is an innovation in the aspect of medicines for treating the diabetes mellitus.

The present invention relates to an application of acetylcholinesterase inhibitor for curing diabetes. The described inhibitor includes all the compounds which can inhibit acetylcholinesterase activity and have the action for curing diabetes. The invented experimental results show that these inhibitors have the actions of inhibiting beta-cell death and reducing blood sugar concentration of diabetic model mouse, and can effectively cure or improve diabetes symptom.

The invention relates to a bis-o-vanillin ethylene diamine schiff base and transitional metal coordination compound and a preparation method thereof, which can solve the problem of the application of a coordination compound prepared by compounding bis-o-vanillin ethylene diamine schiff base serving as a ligand and a transitional metal to a medicament for treating diabetes. The coordination compound is the bis-o-vanillin ethylene diamine schiff base and transitional metal coordination compound prepared by compounding the bis-o-vanillin ethylene diamine schiff base with the transitional metal. The preparation method of the coordination compound comprises the following steps of: dissolving one of 0.02 to 0.03mol of transitional metal vanadium, 0.02 to 0.03mol of cadmium salt or 0.02 to 0.03mol of copper salt and 0.02mol of bis-o-vanillin ethylene diamine schiff base by using 3 to 5mL of methanol or mixed solution of 3 to 5mL of methanol and N,N-dimethyl formamide in the volume ratio of 1:6 respectively; slowly and uniformly mixing; filtering the mixed liquor; diluting the obtained filtrate to 8mL by using methanol; and standing at the temperature of between 18 and 25 DEG C for 5 to 30 days to obtain the coordination compound. The coordination compound has a simple preparation method, can be effectively used for preparing the medicament for treating the diabetes and is an innovation of the medicament for treating the diabetes.

The invention discloses a method for detecting related gene mutations of diabetes drug treatment as well as a special chip and a kit thereof. The method comprises the following steps: taking a genome to be detected from a human tissue as a template, carrying out multiple PCR amplification by a primer group that is designed aiming at special mutant sites and DNA polymerase without 3'-5' end exonclease activity, then hybridizing the obtained PCR product and an allele specific probe on the gene chip, and confirming mutation types of related genes of diabetes drug treatment according to the hybridizing result. The invention can detect known gene mutations closely related to the individual difference of anti-tumor medicine reaction in comprehensive, systemic and high-flux ways and greatly improve the accuracy and the specificity of chip detection.